Literature DB >> 20404969

Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis.

T Vandenberg1, J Younus, S Al-Khayyat.   

Abstract

Entities:  

Keywords:  Febrile neutropenia; adjuvant chemotherapy; breast cancer

Year:  2010        PMID： 20404969      PMCID： PMC2854631          DOI： 10.3747/co.v17i2.498

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  8 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

2.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

3.  Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

Authors:  Hyman B Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric Winer; Harvey Cohen; Judith Wheeler; Larry Norton
Journal:  JAMA       Date:  2005-03-02       Impact factor: 56.272

4.  Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.

Authors:  Lillian Sung; Paul C Nathan; Shabbir M H Alibhai; George A Tomlinson; Joseph Beyene
Journal:  Ann Intern Med       Date:  2007-09-18       Impact factor: 25.391

5.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Authors:  Michele De Laurentiis; Giuseppe Cancello; Diego D'Agostino; Mario Giuliano; Antonio Giordano; Emilia Montagna; Rossella Lauria; Valeria Forestieri; Angela Esposito; Lucrezia Silvestro; Roberta Pennacchio; Carmen Criscitiello; Agnese Montanino; Gennaro Limite; Angelo Raffaele Bianco; Sabino De Placido
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

6.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

Authors:  Stephen Jones; Frankie Ann Holmes; Joyce O'Shaughnessy; Joanne L Blum; Svetislava J Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert L Kirby; John Sandbach; William J Hyman; Donald A Richards; Robert G Mennel; Kristi A Boehm; Wally G Meyer; Lina Asmar; Daniel Mackey; Stefan Riedel; Hyman Muss; Michael A Savin
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.

Authors:  Tomasz P Srokowski; Shenying Fang; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

Review 8.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Authors:  M Clarke; A S Coates; S C Darby; C Davies; R D Gelber; J Godwin; A Goldhirsch; R Gray; R Peto; K I Pritchard; W C Wood
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321
  8 in total
  15 in total

1.  The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.

Authors:  T Younis; D Rayson; C Skedgel
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

2.  Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

Authors:  Gabrielle Rocque; Adedayo Onitilo; Jessica Engel; Erica Pettke; Alice Boshoven; Kyungmann Kim; Shailly Rishi; Bonnie Waack; Kari B Wisinski; Amye Tevaarwerk; Mark E Burkard
Journal:  Breast Cancer Res Treat       Date:  2011-11-08       Impact factor: 4.872

3.  Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.

Authors:  Nuttapong Ngamphaiboon; Tracey L O'Connor; Pooja P Advani; Ellis G Levine; Ellen B Kossoff
Journal:  Med Oncol       Date:  2011-08-05       Impact factor: 3.064

4.  Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.

Authors:  J Younus; T Vandenberg; M Jawaid; M A Jawaid
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

5.  Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Authors:  Mark Clemons; Sasha Mazzarello; John Hilton; Anil Joy; Julie Price-Hiller; Xiaofu Zhu; Shailendra Verma; Anne Kehoe; Mohammed Fk Ibrahim; Marta Sienkiewicz; Carol Stober; Lisa Vandermeer; Brian Hutton; Ranjeeta Mallick; Dean Fergusson
Journal:  Support Care Cancer       Date:  2018-08-11       Impact factor: 3.603

6.  A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.

Authors:  Mova Leung; Joy Florendo; Jessica Kano; Tiffany Marr-Del Monte; Brian Higgins; Robert Myers; Trishala Menon; Glenn Jones
Journal:  Support Care Cancer       Date:  2014-11-26       Impact factor: 3.603

Review 7.  Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.

Authors:  Tallal Younis; Daniel Rayson; Kara Thompson
Journal:  Support Care Cancer       Date:  2012-01-15       Impact factor: 3.603

8.  Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.

Authors:  A K Altwairgi; W M Hopman; M Mates
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

9.  Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.

Authors:  Marc L Fishman; Akhil Kumar; Sharon Davis; William Shimp; William J M Hrushesky
Journal:  J Oncol Pract       Date:  2012-05       Impact factor: 3.840

Review 10.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.